Active ingredientEcopipamCat. No. P-E007-001CAS 112108-00-6Family · Pharmaceutical analytical standards
Ecopipam
A selective antagonist of dopamine D1 and D5 receptors, the first of its class: in paediatric Tourette syndrome it met its primary endpoint in a phase 2b study, published in 2023, followed by a phase 3 study published in 2026. This family brings together the active ingredient, metabolites, labelled standards and other impurities.
Did you know?Before Tourette syndrome it was studied for schizophrenia and for obesity, and in 2020 a study against stuttering in adults also began.
Go to the active ingredient →Active ingredientEcopipamCat. No. P-E007-001CAS 112108-00-6
Active ingredientEcopipam HBrCat. No. P-E007-002CAS 1227675-51-5
MetaboliteEcopipam O-GlucuronideCat. No. P-E007-003
Isotopically labelledEcopipam-d4Cat. No. P-E007-006
Isotopically labelledEcopipam-d4 O-GlucuronideCat. No. P-E007-007
Isotopically labelledN-Desmethyl Ecopipam-d4Cat. No. P-E007-008
Isotopically labelledN-Desmethyl Ecopipam-d4 O-GlucuronideCat. No. P-E007-009
ImpurityN-Desmethyl EcopipamCat. No. P-E007-010CAS 129672-23-7No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.